Biomark expands Quebec lab, doubles testing capacity

Executive Summary

• Biomark Diagnostics Inc. completed a strategic laboratory equipment leasing agreement that substantially doubles its testing capacity in Quebec.
• The expansion is designed to accommodate increased demand from international partnerships and prepare for the imminent commercial launch of its metabolomic-based lung cancer diagnostic assay.
• The upgraded facility aims to serve as a central hub for high-throughput diagnostics, collaborative ventures, and the accelerated rollout of multiple new assays.

Key Details

• Transaction Structure: Strategic laboratory equipment leasing agreement.
• Capacity Impact: Substantially doubled Biomark's testing capacity.
• Strategic Purpose:
  • Prepare for the widespread clinical deployment of the metabolomic-based lung cancer diagnostic assay.
  • Address escalating global demand for non-invasive liquid biopsy diagnostics.
  • Provide advanced diagnostic analytical molecular services to international clients.
  • Expand research capabilities for pharmaceutical and biotechnology companies.
  • Support the accelerated rollout of multiple new assays.
  • Align with the company's laboratory certification and accreditation roadmap.
• Operational Goals:
  • Establish an agile, clinically robust platform for advanced cancer research.
  • Facilitate continuing clinical research collaborations with global health care institutions.
  • Streamline regulatory filings and clinical validation studies for new indications.
  • Enable expansion into international markets.
  • Enable broad deployment through robust clinical partnerships, centralized testing services, and expanded contract research programs.

Notable Quotes

• "Our enhanced laboratory capacity underscores Biomark's unwavering commitment to clinical excellence, innovation and accessibility... Once certified, this laboratory will serve as a pivotal engine for commercialization, revenue generation, strategic partnerships and the widespread clinical deployment of our metabolomic-based diagnostic assays." — Jean-Francois Haince, CSO and General Manager
• "Our team remains intensely focused on achieving key milestones and enhancing long-term shareholder value... This accomplishment strategically positions Biomark at a significant advantage within the diagnostic arena, marking a critical enabler as we continue to scale our AI-enhanced assays and foster collaborations across the entire cancer care spectrum." — Rashid Ahmed Bux, President and CEO